Immediate Impact
89 standout
Citing Papers
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension
2023 Standout
Chronic kidney disease
2021 Standout
Works of Bárbara Ramos being referenced
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials
2004
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Bárbara Ramos | 113 | 99 | 92 | 259 | 135 | 8 | 426 | |
| Emilio Chiurlia | 52 | 22 | 9 | 160 | 172 | 14 | 411 | |
| Kirk Midkiff | 33 | 32 | 40 | 39 | 32 | 10 | 447 | |
| Robert J. Fakheri | 11 | 23 | 14 | 154 | 98 | 9 | 418 | |
| B. O'Connor | 8 | 46 | 19 | 113 | 212 | 15 | 471 | |
| S J Smith | 22 | 13 | 13 | 125 | 66 | 10 | 374 | |
| Tannia Leticia Viveros-Ruiz | 8 | 172 | 14 | 121 | 219 | 7 | 410 | |
| Patrick Gatmaitan | 16 | 65 | 57 | 63 | 55 | 9 | 375 | |
| Bridget Smith | 25 | 29 | 166 | 36 | 36 | 7 | 398 | |
| E Lieberman | 7 | 41 | 14 | 190 | 63 | 12 | 454 | |
| Lee Hebert | 9 | 13 | 70 | 163 | 67 | 13 | 387 |
All Works
Loading papers...